President Donald Trump’s administration took aim at drug-pricing reform this month by holding listening sessions with industry groups and advocates. His administration is pursuing actions it can take with and without Congress to combat the industry’s high drug prices, according to a report from The Hill. The pharmaceutical industry, traditionally a powerful lobbying force on Capitol […]
Featured
First patient transfused with Intercept red blood cells in Phase III trial
Cerus (NSDQ:CERS) said today that the 1st patient was transfused in Puerto Rico in a clinical trial comparing red blood cells processed with its Intercept blood system to conventional red blood cells. Concord, Calif.-based Cerus is developing the Intercept blood system, a pathogen reduction device designed to inactivate a broad range of viruses, bacteria, parasites […]
AdvaMed unveils new tools to assess medical device value
AdvaMed today launched a new value initiative that includes extensive tables of questions to help medical device companies formulate value-based arguments. The value framework also includes tools specifically designed for diagnostic technologies, as well as report on understanding evidence and use cases. “Value” has become an important word in medtech in recent years as government and […]
Aptar Pharma’s nasal spray compliance device wins EMA nod
Aptar Pharma said today that the European Medicines Agency approved its electronic nasal lockout device, e-Lockout. The device is the 1st and only fully-integrated electronic nasal drug delivery device to be approved by a European regulatory authority, according to the company. The e-Lockout device is a part of a multi-year development deal with Takeda Pharmaceuticals […]
Genoa raises $62m Series A for inhaled lung drug
Genoa Pharmaceuticals said today that it raised $62 million in a Series A round to support the development of inhaled therapies for idiopathic pulmonary fibrosis and other severe pulmonary conditions. The round was led by F-Prime Capital Partners and Edmond de Rothschild Investment Partners. Novo AS, RiverVest Venture Partners and TPG Biotech also invested in […]
MannKind shares dip after Q1 sales miss consensus
Shares in MannKind Corp. (NSDQ:MNKD) fell this week after the biopharmaceutical company missed expectations on Wall Street with its 1st quarter results. The Valencia, Calif.-based company pared its losses to -$16.3 million on sales of $3 million for the 3 months ended March 31, for bottom-line growth of 53% compared with the same period last year. […]
Medtech stories we missed this week: May 12, 2017
From Bioness’s new distribution deal to InBrace’s launch of new braces technology, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Obalon receives approval to commercialize in Middle East Obalon Therapeutics announced in a May 11 press release that it has received regulatory approvals in select Middle East […]
Impax shares climb despite Q1 miss
Shares in Impax Laboratories (NSDQ:IPXL) rose earlier this week even though the pharmaceutical company missed expectations on Wall Street with its Q1 results. The Hayward, Calif.-based company posted profits of $7.7 million on sales of $184.4 million for the 3 months ended March 31, for bottom-line loss of -75% on sales loss of -18.2% compared with the same […]
Valeritas reels in losses for Q1
Insulin-delivery device maker Valeritas (NSDQ:VLRX) missed earnings and revenue expectations on Wall Street with its 1st quarter results. The Bridgewater, N.J.-based company pared its losses to -$11.9 million on sales of $4.6 million for the 3 months ended March 31, for bottom-line growth of 30% on sales loss of -8% compared with the same period last year. […]
Amid drug-pricing criticism, industry trade group ousts members
The pharmaceutical industry’s trade group ousted 22 companies earlier this week after it revised membership rules. The move comes as lawmakers in Washington have pressed the pharma industry about U.S. drug prices. The updated membership rules for the Pharmaceutical Research and Manufacturers of America (PhRMA) group mandates that members spend at least $200 million each year […]